Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963544 | 0.89 | PTGS2 (0.48) | PTGS2ALDH1A1RAB9AGAATSHR | |
| SCHEMBL9963521 | 0.89 | PTGS2 (0.48) | PTGS2ALDH1A1RAB9AGAATSHR | |
| SCHEMBL9963545 | 0.89 | PTGS2 (0.51) | PTGS2ALDH1A1RAB9AGAATSHR | |
| SCHEMBL9963604 | 0.89 | PTGS2 (0.41) | PTGS2ALDH1A1RAB9AGAATSHR | |
| SCHEMBL9963553 | 0.88 | PTGS2 (0.47) | PTGS2ALDH1A1RAB9AGAATSHR | |
| SCHEMBL9963695 | 0.88 | PTGS2 (0.49) | PTGS2ALDH1A1RAB9AGAATSHR | |
| SCHEMBL9963526 | 0.87 | PTGS2 (0.47) | PTGS2ALDH1A1RAB9AGAATSHR | |
| SCHEMBL9963593 | 0.87 | PTGS2 (0.46) | PTGS2ALDH1A1RAB9AGAATSHR | |
| SCHEMBL9963603 | 0.87 | PTGS2 (0.53) | PTGS2ALDH1A1RAB9AGAATSHR | |
| SCHEMBL9963654 | 0.86 | PTGS2 (0.39) | PTGS2ALDH1A1RAB9AGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8203001-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8203001-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20090258857-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258857-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258857-A1 | CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | PTGS2 2872/4885ALDH1A1 51/4885RAB9A 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.